| Drug ID: | Drug196 |
|---|---|
| Drug Name: | Desonide |
| CID: | 5311066 |
| DrugBank ID: | DB01260 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03437005, , NCT02624544, , NCT03386032, , NCT03758365, , NCT00828412, , NCT02732314, , NCT02286700, , NCT01467362, , NCT01542138 |
| Molecular Formula: | C24H32O6 |
| Molecular Weight: | 416.5 g/mol |
| Isomeric SMILES: | C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O |
| Synonyms: | DESONIDE; 638-94-8; Prednacinolone; Desonate; Desonida; Topifug; Desilux; Desonidum; Verdeso; Apolar |
| Phase 0: | 0 |
| Phase 1: | 2 |
| Phase 2: | 0 |
| Phase 3: | 3 |
| Phase 4: | 5 |
| Description: | A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1375 | 5311066 | Desonide | 301 | ANXA1 | Homo sapiens (human) | None | |
| dt1376 | 5311066 | Desonide | 2908 | NR3C1 | Homo sapiens (human) | Glucocorticoid receptor agonist | |
| dt1377 | 5311066 | Desonide | 367 | AR | Homo sapiens (human) | None | |
| dt1378 | 5311066 | Desonide | 2101 | ESRRA | Homo sapiens (human) | Modulator | |
| dt1379 | 5311066 | Desonide | 2103 | ESRRB | Homo sapiens (human) | Modulator | |
| dt1380 | 5311066 | Desonide | 2104 | ESRRG | Homo sapiens (human) | Modulator | |
| dt1381 | 5311066 | Desonide | 2908 | NR3C1 | Homo sapiens (human) | None | |
| dt1382 | 5311066 | Desonide | 2101 | ESRRA | Homo sapiens (human) | 37713619 | Modulator |
| dt1383 | 5311066 | Desonide | 2103 | ESRRB | Homo sapiens (human) | 37713619 | Modulator |
| dt1384 | 5311066 | Desonide | 2104 | ESRRG | Homo sapiens (human) | 37713619 | Modulator |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05341401 | Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis | PHASE2|PHASE3 | UNKNOWN | Assiut University | Ulcerative Colitis Chronic | DRUG: Budesonide MMX|DRUG: Prednisolone | Details |
| NCT04314375 | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis | PHASE4 | RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Low Dose Budesonide|DRUG: High Dose Budeson… | Details |
| NCT04233463 | The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease | NA | UNKNOWN | Hillel Yaffe Medical Center | Crohn Disease | DIETARY_SUPPLEMENT: Modulen|DRUG: Budesonide | Details |
| NCT03412682 | To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis | PHASE3 | COMPLETED | Ferring Pharmaceuticals | Colitis, Ulcerative | DRUG: Budesonide (6 mg)|DRUG: Budesonide (9 mg)|D… | Details |
| NCT02586259 | Effectiveness of Cortiment® in Patients With Ulcerative Colitis | NULL | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | DRUG: budesonide MMX® | Details |
| NCT02550418 | Budesonide 9 mg Capsules in Active UC | PHASE2 | COMPLETED | Dr. Falk Pharma GmbH | Colitis, Ulcerative | DRUG: Budesonide | Details |
| NCT06719622 | Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum | PHASE2|PHASE3 | ENROLLING_BY_INVITATION | Medical University of Warsaw | Crohn Disease (CD) | DRUG: budesonide|DRUG: omeprazole (proton pump in… | Details |
| NCT01783106 | Antibiotics and Hydroxychloroquine in Crohn's | PHASE2 | COMPLETED | Royal Liverpool University Hospital | Crohn's Disease | DRUG: Ciprofloxacin|DRUG: Doxycycline|DRUG: Hydro… | Details |
| NCT01532648 | Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Budesonide MMX®|DRUG: Placebo|DRUG: 5-ASA | Details |
| NCT01349673 | The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | TERMINATED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide Foam | Details |
| NCT01100112 | (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Colitis, Ulcerative | DRUG: Budesonide | Details |
| NCT01086553 | 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease | PHASE3 | COMPLETED | Dr. Falk Pharma GmbH | Crohn´s Disease | DRUG: budesonide|DRUG: budesonide | Details |
| NCT01008423 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide|DRUG: Placebo | Details |
| NCT01008410 | Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Proctitis|Proctosigmoiditis | DRUG: Budesonide|DRUG: Placebo | Details |
| NCT00805285 | The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis | PHASE2 | TERMINATED | University of Maryland, Baltimore | Inflammatory Bowel Disease|Ulcerative Colitis | DRUG: Combination Oral Budesonide and Rectal Hydr… | Details |
| NCT00801723 | (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Budesonide MMX 6 mg Tablet|DRUG: Placebo Ta… | Details |
| NCT00747110 | Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) | PHASE3 | COMPLETED | Dr. Falk Pharma GmbH | Colitis, Ulcerative | DRUG: budesonide|DRUG: mesalazine | Details |
| NCT00679432 | (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | PROCEDURE: Blood sampling, endoscopy|DRUG: budeso… | Details |
| NCT00679380 | (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | PROCEDURE: Blood sampling, endoscopy|DRUG: Budeso… | Details |
| NCT00554710 | Top Down Versus Step Up Strategies in Crohn's Disease | PHASE4 | COMPLETED | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Crohn's Disease | DRUG: infliximab+azathioprine|DRUG: methylprednis… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Reevaluating therapeutic strategies in Crohn's disease: Comparing Modulen and b…
PMID: 40539199
Year: 2025
Relationship Type:
Treatment
Score: 6.5
This article explores the significant implications of the study by Ovadia et al, which innovatively compares the efficacy of a nutritional interventi…
Oral delivery of tunable oxidation-responsive budesonide-loaded nanoparticles e…
PMID: 40513667
Year: 2025
Relationship Type:
Treatment
Score: 6.5
The rising global prevalence and socio-economic impact of Inflammatory Bowel Disease (IBD) highlight the pressing demand of innovative solutions. Dru…
A case of IgA nephropathy associated with Crohn's disease treated with enteric-…
PMID: 40447912
Year: 2025
Relationship Type:
Treatment
Score: 6.5
The gut-kidney axis has recently gained attention as a pathogenesis of IgA nephropathy (IgAN). In fact, the efficacy of target-release formulation of…
Oral Budesonide in Oncology: A Novel Approach to Managing Gastrointestinal Immu…
PMID: 40214925
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Budesonide is a potent topical glucocorticosteroid with limited systemic activity owing to its extensive hepatic first-pass metabolism following oral…
Effect of Modulen vs budesonide on clinical response and mucosal healing in Cro…
PMID: 39926225
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Mucosal healing has become an important goal of Crohn's disease (CD) treatments. Modulen, enriched with transforming growth factor-beta 2…
Tofacitinib and budesonide treatment affect stemness and chemokine release in I…
PMID: 39885201
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Restoration of the intestinal epithelial barrier is crucial for achieving mucosal healing, the therapeutic goal for inflammatory bowel disease (IBD).…
Actual Use of Budesonide Enteric-Coated Capsules for Crohn's Disease in Japan: …
PMID: 39864854
Year: 2025
Relationship Type:
Adverse Effect
Score: 6.5
Using a large health insurance database in Japan, we examined the real-world usage of budesonide enteric-coated capsules (BUD) in treating Crohn's di…
Budesonide Versus Mesalamine in Microscopic Colitis: A Comparative Meta-analysi…
PMID: 39042479
Year: 2025
Relationship Type:
Adverse Effect
Score: 6.5
BACKGROUND: Microscopic colitis (MC) is an inflammatory bowel disease of autoimmune origin that causes chronic watery diarrhea. Medications, includin…
The Role of Nanoparticle Morphology on Enhancing Delivery of Budesonide for Tre…
PMID: 38888094
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic and recurrent inflammatory disease that affects the gastrointestinal tract. The major hurdles impeding …
Oral Budesonide and low serum albumin levels at surgery are associated with a h…
PMID: 38616140
Year: 2024
Relationship Type:
Association
Score: 6.5
BACKGROUND AND AIMS: The terminal ileum is the most frequent site of Crohn's Disease (CD) that necessitates surgery. Of the postoperative complicatio…
Effectiveness and safety of vedolizumab induction with or without budesonide in…
PMID: 38030966
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to se…
Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile coli…
PMID: 37713991
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Clostridioides difficile infection (CDI) induces intense acute inflammatory responses through toxin release. A combination of an…
Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX vers…
PMID: 37538919
Year: 2023
Relationship Type:
Association
Score: 6.5
BACKGROUND: Low bioavailability steroids, including beclomethasone dipropionate (BDP) and budesonide MMX, have been developed to ensure colonic targe…
Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-modera…
PMID: 37538282
Year: 2023
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Budesonide MMX((R)) is approved for induction of remission in mild-to-moderate active ulcerative colitis (UC) in adults in whom 5-ASA i…
Budesonide-liposomes inclusion complex in thermosensitive gel alleviates DSS-in…
PMID: 37272387
Year: 2023
Relationship Type:
Treatment
Score: 6.5
PURPOSE: A novel formulation for Ulcerative Colitis (UC) treatment by rectal administration with budesonide liposomes (Bud (Lip)) and thermosensitive…
Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-2…
PMID: 37184747
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is characterized by chronic inflammation along the gastrointestinal tract. For IBD effective treatment, developing a…
Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling…
PMID: 37127609
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Colon-targeted oral drug delivery systems (CDDSs) are desirable for the treatment of ulcerative colitis (UC), which is a disease with high relapse an…
A pediatric case of IgA nephropathy benefitting from targeted release formulati…
PMID: 37041389
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: The best treatment for IgAN is still debated. The trials NEFIGAN and NEFIGARD have demonstrated that TRF-budesonide (Nefecon) efficiently…
Possible genetical predictors of efficacy and safety of budesonide-MMX in patie…
PMID: 36811412
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Budesonide-MMX is a topically active corticosteroid degraded by cytochrome-P450 enzymes, resulting in favorable side-effect profile. We a…
Form & formulation approaches for COntRollable Release in 3D printed Colonic Ta…
PMID: 36754183
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) represents a group of chronic and debilitating inflammatory diseases affecting various parts of the gastrointestinal…